Skip to main content

Ribociclib + Nonsteroidal Aromatase Inhibitor Benefits Early Breast Cancer

Medically reviewed by Judith Stewart, BPharm. Last updated on March 21, 2024.

By Lori Solomon HealthDay Reporter

THURSDAY, March 21, 2024 -- Ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) significantly improves invasive disease-free survival among patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer, according to a study published in the March 21 issue of the New England Journal of Medicine.

Dennis Slamon, M.D., Ph.D., from the David Geffen School of Medicine at the University of California in Los Angeles, and colleagues conducted a phase 3 trial in which patients with HR-positive, HER2-negative early breast cancer were randomly assigned (1:1) to receive ribociclib (400 mg per day for three weeks, followed by one week off, for three years) plus an NSAI (letrozole [2.5 mg per day] or anastrozole [1 mg per day] for at least five years) or an NSAI alone.

The researchers observed a significant invasive disease-free survival benefit with ribociclib plus an NSAI versus an NSAI alone. Invasive disease-free survival at three years was 90.4 percent with ribociclib plus an NSAI versus 87.1 percent with an NSAI alone (hazard ratio for invasive disease, recurrence, or death, 0.75). For distant disease-free survival and recurrence-free survival, results also favored ribociclib plus an NSAI. No new safety signals emerged.

"These results support the use of ribociclib in the treatment of HR-positive, HER2-negative early breast cancer," the authors write.

The study was funded by Novartis, the manufacturer of ribociclib.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted March 2024

Read this next

Donepezil Not Beneficial for Cognitive Impairment in Breast Cancer Survivors

FRIDAY, May 24, 2024 -- A once-daily dose of donepezil does not improve cognitive function among breast cancer survivors exposed to chemotherapy one to five years earlier...

ASCO: Survivors of Early Breast Cancer Can Successfully Attempt Pregnancy

THURSDAY, May 23, 2024 -- Most survivors of stage 0 to III breast cancer who attempt pregnancy postdiagnosis are able to become pregnant and have a live birth, according to a...

4-Dimensional Model Can Predict Lymph Node Metastases in Breast Cancer

THURSDAY, May 23, 2024 -- A deep learning model using tumor dynamic contrast-enhanced breast magnetic resonance imaging (MRI) has high sensitivity for identifying lymph node...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.